Introduction
============

Random-pattern skin flaps are commonly used in plastic surgery to cover skin defects, which are caused by trauma, oncologic resection, or congenital conditions ([@B35]; [@B10]; [@B38]; [@B14]). However, necrosis of partial flaps, one of the most frequent post-operative complications, limits their clinical application, as it restricts the length-to-width ratio of flaps to 1.5 or 2:1 ([@B13]). The viability of random flaps depends on an adequate blood supply; thus, tissue necrosis in distal random flaps is typically due to a lack of angiogenesis ([@B32]). After establishing a random flap, a new vasoganglion starts to form from the pedicle bed of the flap toward the distal end. Therefore, angiogenesis is infrequent in the distal part of the flap ([@B29]). After vascular regeneration in a cutaneous flap, reperfusion and restoration of blood supply result in IRI by promoting necrosis ([@B23]). Oxidative stress and apoptosis are two major mechanisms of IRI and are key factors in the necrosis of random-pattern flaps ([@B5]). Thus, ischemic necrosis of random skin flaps can be ameliorated by promoting angiogenesis and inhibiting oxidative stress and apoptosis.

Autophagy, the degradation of cytosolic macromolecules and organelles in lysosomes, is crucial in angiogenesis and IRI ([@B27]; [@B3]). Activation of autophagy up-regulates AKT phosphorylation in endothelial cells, leading to promotion of angiogenesis ([@B26]). Moreover, it alleviates cerebral IRI after inhibition of mammalian target of rapamycin complex-1 (mTOR1) ([@B26]). Interestingly, calcitriol enhances the viability of random flaps by activating autophagy, which alleviates IRI and promotes angiogenesis ([@B49]; [@B3]). Therefore, an agent that promotes autophagy and angiogenesis and inhibits oxidative stress and apoptosis could enhance the survival of random skin flaps.

Traditional Chinese Medicine is widely used in China to treat ischemic diseases ([@B33]). Sal B is a water-soluble compound purified from *Salvia miltiorrhiza*, a well-known source material used in TCM ([@B2]; [@B20]). Sal B stimulates bone-marrow angiogenesis by inducing peroxisome proliferator-activated receptor γ (PPARγ) and Runx2 in prednisone-treated rats ([@B20]). Moreover, it reduces oxidative stress and neurocyte apoptosis in rats with cerebral small vessel disease via the STAT3/VEGF signaling pathway ([@B39]). It also induces autophagy and has anti-cancer effects via the AKT/mTOR signaling pathway in hepatocellular carcinoma cells ([@B9]); ameliorates cerebral IRI by inhibiting TLR4/MyD88 signaling pathway ([@B40]); and promotes angiogenesis and autophagy in acute myocardial infarction ([@B22]). However, the effects of Sal B on random-pattern cutaneous flaps are unclear, and the underlying mechanisms of any effects are unknown.

We investigated the effects of Sal B on the survival of random-pattern cutaneous flaps and the underlying mechanism, with a focus on the role of autophagy.

Materials and Methods {#s1}
=====================

Animals
-------

Healthy Sprague-Dawley rats (male: 250--300 g) were provided by Wenzhou Medical University (License No. SCXK \[ZJ\] 2005--0019). The Guide for the Care and Use of Laboratory Animals of the China National Institutes of Health was followed for procedures involving animals. All procedures were approved by the Animal Care and Use Committee of Wenzhou Medical University (wydw 2017-0022). All efforts were made to minimize the suffering of the rats. All rats were euthanized by pentobarbital sodium overdose. Seventy-two rats were randomly separated into control, Sal B, and Sal B + 3-methyladenine groups (*n* = 24 each).

Reagents and Antibodies
-----------------------

Sal B (C~36~H~30~O~16~; purity, 98.5%) was acquired from Tauto Biotech (Shanghai, China). The H&E Staining Kit, DAB developer, and pentobarbital sodium were purchased from Solarbio Science & Technology (Beijing, China). SOD, GSH, and MDA assay kits were acquired from Jiancheng Technology (Nanjing, China). The primary antibody against cadherin 5 was acquired from Boster Biological Technology (A02632-2; Wuhan, China). The primary antibody against GAPDH was purchased from Biogot Technology (AP0063; Shanghai, China). Primary antibodies against VEGF, SOD1, VPS34, MMP9, HO1, CTSD, and CAPS3 were acquired from Proteintech Group (19003-1, 10269-1, 12452-1, 10375-2, 10701-1, 21327-1, and 19677-1; Chicago, IL, United States). Primary antibodies against CYC, Bax, and eNOS were purchased from Cell Signaling Technology (12994, 14796, and 32027; Beverly, MA, United States). The primary antibody against SQSTM1/p62 was purchased from Abcam (ab56416; Cambridge, United Kingdom). Primary antibodies against LC3B and 3MA were purchased from Sigma-Aldrich Chemical Company (L7543 and M9281; Milwaukee, WI, United States). HRP-conjugated IgG secondary antibody was purchased from Santa Cruz Biotechnology (Dallas, TX, United States). FITC-conjugated IgG secondary antibody was obtained from Boyun Biotechnology (Nanjing, China), and DAPI solution was purchased from Beyotime Biotechnology (Jiangsu, China). The BCA Kit was acquired from Thermo Fisher Scientific (Rockford, IL, United States). The ECL Plus Reagent Kit was purchased from PerkinElmer Life Sciences (Waltham, MA, United States).

Animal Model
------------

Rats were anesthetized by intraperitoneal injection of 40 mg/kg pentobarbital sodium 2% (w/v). The modified McFarlane flap model in the rat dorsum (in the same position in each rat) was performed as previously reported ([@B13]). A caudal skin/panniculus carnosus flap of 3 cm × 9 cm was outlined on the back of the rat, and the skin flap was separated from the underlying fascia. Next, the right and left sacral arteries were excised. Finally, the flap was sutured to the donor bed using 4-0 silk and a wedged-on cutting needle. The random skin flap area was separated into the proximal (area I), intermediate (area II), and distal (area III) zones, each of equal size.

Group Assignment and Drug Administration
----------------------------------------

Rats in the Sal B group received an intraperitoneal 40 mg/kg/day injection of Sal B daily. Those in the Sal B + 3MA group received an intraperitoneal injection of 40 mg/kg/day Sal B and 0.5 mg/kg/day 3MA daily. The control group (*n* = 24) received an equal volume of saline daily. The injections were performed from 7 days preoperatively until the rats were euthanized. The rats were housed individually in standard experimental cages in an environment-controlled room and were provided with standard rat chow and water *ad libitum*. All animals were euthanized by pentobarbital sodium overdose at 7 days.

General Observation and Flap Survival Assessment
------------------------------------------------

Macroscopic changes in flaps were noted for 7 days after the operation; these included appearance, color, texture, and hair condition. Survival area was evidenced by pink and soft skin with new hair growth, whereas necrotic area was evidenced by scabbing, hardening, and dark nidus without new hair growth. At post-operative days 3 and 7, flap survival areas were measured using superimposition of photographs on graph paper, and the percentages were calculated by ImageJ software (National Institutes of Health, Bethesda, MD, United States) as: extent of viable area × 100% ÷ total area.

Laser Doppler Blood Flow Measurement
------------------------------------

Laser Doppler blood flow measurements were performed to evaluate the blood supply to the flaps. At day 7 post-operatively, six rats per group were anesthetized and scanned using a Laserflo BPM (Vasamedic, Saint Paul, MN, United States), with 15 cm × 15 cm area and 256 × 256 pixels. The LDBF protocol was as previously described ([@B43]). LDBF generally offers deeper penetration enabling enhanced visualization of small vessels below the tissue surface, perfect for angiogenesis evaluation. Blood supply was visualized using the LDBF strong signal (green, yellow, and red), the area of which was quantified using ImageJ software (NIH, Bethesda, MD, United States). The percentage of the flap area with a blood supply was calculated as: strong signal area × 100% ÷ total area.

Tissue Edema
------------

Tissue edema was assessed by measuring the water content of the flaps. On day 7 post-operatively, flap tissues were harvested, and dehydrated in an autoclave at 50°C. The specimens were weighed daily until constant weight over 2 days. The water content was determined as (\[wet weight -- dry weight\] ÷ wet weight) × 100%.

Hematoxylin and Eosin Staining
------------------------------

After the rats had been euthanized, three samples (0.5 cm × 0.5 cm) of central tissue from area II were collected, post-fixed in 4% (v/v) paraformaldehyde for 1 day, and embedded in paraffin wax for transverse sectioning. The sections (4 μm thickness) were mounted on poly [L]{.smallcaps}-lysine-coated slides for H&E staining. Under a light microscope (20× magnification), the thickness of granulation tissue, edema, and angiogenesis were observed. In addition, the number of microvessels per unit area (/mm^2^) was counted manually.

SOD Activity, GSH Level, and MDA Content
----------------------------------------

SOD, GSH, and MDA assays were conducted to evaluate the oxidative stress levels of ischemic flaps. At day 7 post-operatively, tissue samples (0.5 cm × 0.5 cm) were separated from the middle area of area II flaps (*n* = 6 per group), weighed, homogenized, and diluted to 10% (v/v) in an ice bath. The homogenate was centrifuged at 3,500 rpm for 15 min and the supernatant was harvested and its SOD activity (xanthine oxidase method), GSH level (modified 5,5′-dithiobis \[2-nitrobenzoic acid\] method), and MDA content (modified thiobarbituric acid test) were determined as previously described.

Immunohistochemistry (IHC)
--------------------------

Six sections of the middle part of area II of the flaps were deparaffinized in xylene and rehydrated through a graded ethanol series. After washing, the sections were blocked in 3% (v/v) H~2~O~2~ and treated with 10.2 mM sodium citrate buffer for 20 min at 95°C. After blocking in 10% (w/v) bovine serum albumin for 10 min, the sections were incubated with antibodies against CD34 (1:100) VEGF (1:300), cadherin 5 (1:100), caspase 3 (1:200), and SOD1 (1:100) overnight at 4°C. Next, the sections were incubated with an HRP-conjugated secondary antibody and counterstained with hematoxylin. Flap tissues were imaged at 20× magnification using the DP2-TWAN image-acquisition system (Olympus, Corp., Tokyo, Japan). Images were analyzed using Image-Pro Plus software (Media Cybernetics, Rockville, MD, United States) for the integral absorbance quantification of VEGF-, cadherin 5-, caspase 3-, SOD1-, and CTSD-, and CD34-positive blood vessels. Six random fields of three random sections of each tissue sample were quantified.

Immunofluorescence
------------------

Six sections of area II were deparaffinized in xylene and rehydrated through a graded ethanol series. After washing, the sections were treated with 10.2 mM sodium citrate buffer for 20 min at 95°C, and permeabilized with 0.1% (v/v) PBS-Triton X-100 for 30 min. After blocking in 10% (v/v) bovine serum albumin in PBS for 1 h, the slides were incubated at 4°C overnight with a primary antibody against LC3 (1:200). Next, the slides were washed three times for 10 min each at room temperature and incubated with FITC-conjugated secondary antibody for 1 h at room temperature. The slides were visualized under a fluorescence microscope (Olympus). The percentage of LC3-positive cells in the dermal layer was determined by counting in six random fields of three random sections from each tissue sample.

Western Blotting
----------------

After the rats had been euthanized, samples (0.5 cm × 0.5 cm) from the middle of area II flaps (*n* = 6) were separated for Western blot analyses. After homogenization, the protein concentration was determined using the BCA assay. Proteins (60 μg) were separated in 12% (w/v) gels and transferred to polyvinylidene difluoride membranes (Roche Applied Science, Indianapolis, IN, United States). After blocking in 10% (w/v) non-fat milk for 2 h, the membranes were incubated with the following primary antibodies at 4°C overnight: VEGF (1:1,000), MMP9 (1:1,000), cadherin 5 (1:1,000), HO1 (1:1,000), eNOS (1:1,000), SOD1 (1:1,000), Bax (1:1000), CYC (1:1,000), caspase 3 (1:1,000), Beclin1 (1:1,000), p62 (1:1,000), LC3 (1:500), VPS34 (1:1,000), CTSD (1:1,000), and GAPDH (1:1,000). The membranes were incubated with the HRP-conjugated IgG secondary antibody (1:5,000) for 2 h at room temperature. Bands were visualized using the ECL Plus Reagent Kit and band intensity was quantified by Image Lab 3.0 software (Bio-Rad, Hercules, CA, United States).

Statistical Analyses
--------------------

Statistical analyses were conducted using SPSS ver. 19 software (Chicago, IL, United States). Data are presented as means ± SEM. Comparisons of means between two groups were performed using the Student's *t*-test. *p*-Values less than 0.05 were considered statistically significant.

Results
=======

Effects of Sal B on the Skin Flaps
----------------------------------

On day 3, area III of the flaps exhibited necrosis, as evidenced by a dark and brown nidus, which tended to spread to area II. There were no significant differences in the flap survival area between the two groups (Figure [1A](#F1){ref-type="fig"}). On day 7 in both groups, area I survived, whereas the necrosis in area III had darkened and spread to area II, with scabbing and hardening (Figure [1A](#F1){ref-type="fig"}). The Sal B group showed a significantly larger mean survival area than the control group (65.66 ± 10.20 and 46.94 ± 14.62%, respectively; *p* = 0.028; Figure [1B](#F1){ref-type="fig"}). In the control group, the distal part of the flaps was swollen and bruised, with subcutaneous venous blood stasis (Figure [1C](#F1){ref-type="fig"}). These signs were less apparent in the Sal B group. The water content of tissue was significantly lower in the Sal B group (48.49 ± 7.34%) than in the control group (59.72 ± 7.62%; *p* = 0.027; Figure [1D](#F1){ref-type="fig"}). Moreover, the Sal B group showed a greater area of blood flow than the control group (Figure [1E](#F1){ref-type="fig"}). The area of vascular flow was significantly larger in the Sal B group than in the control group (40.08 ± 9.86 and 21.08 ± 7.71%, respectively; *p* = 0.004; Figure [1F](#F1){ref-type="fig"}). Flaps in the Sal B group contained a greater number of microvessels than the control group (Figure [1G](#F1){ref-type="fig"}). The MVD of area II in the Sal B group was 32.69 ± 8.61/mm^2^, significantly greater than that in the control group (19.41 ± 7.31/mm^2^; *p* = 0.016; Figure [1H](#F1){ref-type="fig"}). Sal B treatment increased the number of CD34-positive vessels (34.73 ± 8.91/mm^2^ in the Sal B group and 16.34 ± 4.06/mm^2^ in the control group; *p* = 0.001; Figures [1I,J](#F1){ref-type="fig"}).

![Effects of Sal B on random skin flaps vitality. **(A)** Digital photographs of flap survival of the Control and Sal B group on post-operative days 3 and 7 (scale bar: 2 cm). **(B)** Histogram of percentages of flap survival area on post-operative day 7. **(C)** Digital photographs of the inner side of skin flaps in each group on post-operative day 7 showing tissue edema (scale bar: 2 cm). **(D)** Histogram of percentages of tissue water content of skin flaps. **(E)** LDBF imaging showing vascular flow and blood supply in skin flaps on post-operative day 7 (scale bar: 2 cm). **(F)** Histogram of percentages of area of blood supply. **(G)** H&E staining of microvessels in area II of skin flaps (original magnification, 200×; scale bar: 50 μm). **(H)** Histogram of MVDs by H&E staining. **(I)** IHC for CD34 in area II of skin flaps (original magnification: 200×; scale bar: 50 μm). **(J)** Histogram of CD34-positive vessel densities. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 vs. the control group. Data are means ± SEM (*n* = 6 per group).](fphar-09-01178-g001){#F1}

Sal B Promotes Angiogenesis in Areas of Ischemia
------------------------------------------------

Vascular endothelial growth factor, MMP9, and cadherin 5 levels were evaluated by IHC. As shown in Figure [2A](#F2){ref-type="fig"}, VEGF was detected in vessels and stromal cells in area II, and at a higher level in the Sal B group than in the control group (*p* = 0.015; Figure [2B](#F2){ref-type="fig"}). Cadherin 5 expression in vessels and stromal cells (Figure [2C](#F2){ref-type="fig"}) was also higher in the Sal B group than in the control group (*p* = 0.034; Figure [2D](#F2){ref-type="fig"}). Western blotting showed that MMP9, VEGF, and cadherin 5 levels were significantly higher in the Sal B group than in the control group (*p* = 0.001, 0.001, and \<0.001, respectively; Figures [2E](#F2){ref-type="fig"}--[J](#F2){ref-type="fig"}).

![Sal B promotes angiogenesis in ischemic random skin flaps. Rats were killed and the samples in middle part of flap area II were harvested for analysis on post-operative day 7. **(A,C)** IHC of VEGF and cadherin 5 expression of skin flaps in the Control and Sal B group (original magnification: 200×; scale bar: 50 μm). **(B**,**D)** Histograms of optical density values of VEGF and cadherin 5 by IHC, respectively. **(E**--**G)** Western blotting of MMP9, VEGF, and cadherin 5 levels of skin flaps in the Control and Sal B group, corrected by GAPDH as internal control. The gels have been run under the same experimental conditions. The original images are available in Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}. **(H**--**J)** Histograms of optical density values of MMP9, VEGF, and cadherin 5 in the two groups as determined by Western blotting. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 vs. the control group. Data are means ± SEM (*n* = 6 per group).](fphar-09-01178-g002){#F2}

Sal B Reduces Apoptosis in Areas of Ischemia
--------------------------------------------

Caspase 3 levels in the dermis layer of flap area II were lower in the Sal B group than in the control group, as determined by IHC (Figure [3A](#F3){ref-type="fig"}). The integral absorbance of caspase 3 in the Sal B group was significantly lower than that in the control group (*p* \< 0.044) (Figure [3B](#F3){ref-type="fig"}). Bax, CYC, and caspase 3 levels were also determined by Western blotting (Figures [3C](#F3){ref-type="fig"}--[E](#F3){ref-type="fig"}, respectively). The CYC level was significantly higher in the control group than in the Sal B group (*p* = 0.001; Figure [3F](#F3){ref-type="fig"}). However, Bax and caspase 3 levels were lower in the Sal B group than in the control group (*p* = 0.001 and 0.013, respectively; Figures [3G,H](#F3){ref-type="fig"}).

![Sal B inhibits apoptosis in random skin flaps. Rats were killed and the samples in middle part of flap area II were harvested for analysis on post-operative day 7. **(A)** Caspase 3 expression in skin flaps of the Control and Sal B groups, evaluated by IHC (original magnification: 200×; scale bar: 50 μm). **(B)** Histogram of optical density values of Caspase 3 expression by IHC. **(C**--**E)** Western blotting for protein levels of Bax, CYC, and caspase 3, respectively, corrected by GAPDH as internal control. The gels have been run under the same experimental conditions. The original images are available in Supplementary Figure [S1B](#SM1){ref-type="supplementary-material"}. **(F**--**H)** Histograms of optical density values of Bax, CYC, and caspase 3 as determined by Western blotting. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 vs. the control group. Data are means ± SEM (*n* = 6 per group).](fphar-09-01178-g003){#F3}

Sal B Reduces Oxidative Stress in Areas of Ischemia
---------------------------------------------------

SOD, SOD1, eNOS, HO1, GSH, and MDA levels were determined to evaluate the magnitude of oxidative stress in the flaps. SOD1 expression (by IHC) and integral absorbance in the dermis were higher in the Sal B group than in the control group (*p* = 0.024; Figures [4A,B](#F4){ref-type="fig"}). Furthermore, Western blotting indicated that SOD1, eNOS, and HO1 levels (Figures [4C](#F4){ref-type="fig"}--[E](#F4){ref-type="fig"}, respectively) were significantly higher in the Sal B group than in the other groups (*p* = 0.004, 0.022, and 0.026, respectively; Figures [4F](#F4){ref-type="fig"}--[H](#F4){ref-type="fig"}). The Sal B group had a higher mean SOD level (59.33 ± 13.20 U mg^-1^ protein^-1^) than the control group (34.83 ± 10.65 U mg^-1^ protein^-1^; *p* = 0.005; Figure [4I](#F4){ref-type="fig"}). The mean GSH level in the Sal B group was 2.23 ± 0.45 nM mg^-1^ protein^-1^ compared to 1.60 ± 0.30 nM mg^-1^ protein^-1^ in the control group (*p* = 0.018; Figure [4J](#F4){ref-type="fig"}). The mean MDA level in the Sal B group was 40.67 ± 5.05 nM mg^-1^ protein^-1^ compared to 60.67 ± 8.31 nM mg^-1^ protein^-1^ in the control group (*p* = 0.001; Figure [4K](#F4){ref-type="fig"}).

![Sal B reduces oxidative stress in random skin flaps. Rats were killed and the samples in middle part of flap area II were harvested for analysis on post-operative day 7. **(A)** SOD1 expression in skin flaps of the Control and Sal B groups, assessed by IHC (original magnification: 200×; scale bar: 50 μm). **(B)** Histogram of optical density values of SOD1 by IHC. **(C--E)** Western blotting for protein levels of SOD1, eNOS, and HO1, respectively, corrected by GAPDH as internal control. The gels have been run under the same experimental conditions. The original images are available in Supplementary Figure [S1C](#SM1){ref-type="supplementary-material"}. **(F--H)** Histograms of optical density values of SOD1, eNOS, and HO1 as determined by Western blotting. **(I)** Total SOD activity by xanthine oxidase method. **(J)** GSH level by modified 5,5′-dithiobis \[2-nitrobenzoic acid\] method. **(K)** MDA level by modified thiobarbituric acid test. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 vs. the control group. Data are means ± SEM (*n* = 6 per group).](fphar-09-01178-g004){#F4}

Sal B Activates Autophagy in Areas of Ischemia
----------------------------------------------

Beclin1 and VPS34 are localized to the pre-autophagosomal compartment, and LC3II is present in the autophagosome membrane. Therefore, we analyzed Beclin1, VPS34, and LC3II levels as markers of autophagosomes, that of CTSD as a marker of autolysosomes, and that of p62 to monitor autophagic degradation (Figure [5A](#F5){ref-type="fig"}). The frequency of LC3II-positive cells in the dermis in the Sal B group was higher than that in the control group (Figure [5B](#F5){ref-type="fig"}). The CTSD level and integral absorbance in the dermis were higher in the Sal B group than in the control group (*p* = 0.003; Figures [5C,D](#F5){ref-type="fig"}). Furthermore, Western blotting showed that Beclin1, LC3II, VPS34, CTSD, and p62 levels (Figures [5E](#F5){ref-type="fig"}--[G](#F5){ref-type="fig"}) were significantly higher in the Sal B group than in the control group (*p* = 0.015, 0.002, 0.001, and 0.018, respectively), whereas that of p62 was lower in the Sal B group (*p* = 0.024).

![Sal B activates autophagy in random skin flaps. Rats were killed and the samples in middle part of flap area II were harvested for analysis on post-operative day 7. **(A)** Autophagy level in skin flaps were estimated by immunofluorescence staining of LC3II: autophagosomes (green) in the dermis in area II in each group; nuclei counterstained with DAPI (blue) (scale bar: 15 μm). **(B)** Histogram of frequency of LC3II-positive cells. **(C)** CTSD expression by IHC (original magnification: 200×; scale bar: 50 μm). **(D)** CTSD levels in random skin flaps as estimated by Western blotting. **(E,F)** Beclin1, LC3II, CTSD, VPS34, and p62 levels by Western blotting, respectively, corrected by GAPDH as internal control. The gels have been run under the same experimental conditions. The original images are available in Supplementary Figure [S1D](#SM1){ref-type="supplementary-material"}. **(G)** Histograms of optical density values of Beclin1, LC3II, CTSD, VPS34, and p62 expressions as determined by Western blotting. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 vs. the control group. Data are means ± SEM (*n* = 6 per group).](fphar-09-01178-g005){#F5}

Inhibition of Autophagy Reverses the Effects of Sal B
-----------------------------------------------------

Immunofluorescence staining of autophagosomes in area II was performed (Figure [6A](#F6){ref-type="fig"}). The frequency of LC3II-positive cells in the dermis in the Sal B group was greater than that in the Sal B + 3MA group (*p* = 0.002; Figure [6B](#F6){ref-type="fig"}). Western blotting indicated that Beclin1, VPS34, CTSD, and LC3II levels were significantly higher in the Sal B group than in the Sal B + 3MA group (*p* = 0.034, 0.022, 0.002, and 0.013, respectively; Figures [6C,D](#F6){ref-type="fig"}), as were those of MMP9 and cadherin 5 (*p* = 0.043 and 0.047, respectively; Figures [6C,D](#F6){ref-type="fig"}) and SOD1, eNOS, and HO1 (*p* = 0.030, 0.028, and 0.034, respectively; Figures [6E,F](#F6){ref-type="fig"}) but not VEGF (*p* = 0.209; Figures [6C,D](#F6){ref-type="fig"}). By contrast, the p62, CYC, Bax, and caspase 3 levels were significantly lower in the Sal B group than in the Sal B + 3MA group (*p* = 0.002, 0.008, 0.018, and 0.008, respectively; Figures [6E,F](#F6){ref-type="fig"}). The mean SOD level was higher in the Sal B group (59.33 ± 13.20 U mg^-1^ protein^-1^) than in the Sal B + 3MA group (44.17 ± 6.37 U mg^-1^ protein^-1^; *p* = 0.030; Figure [6G](#F6){ref-type="fig"}). The mean GSH level in the Sal B group was 2.23 ± 0.45 nM mg^-1^ protein^-1^ compared to 1.73 ± 0.27 nM mg^-1^ protein^-1^ in the Sal B + 3MA group (*p* = 0.042; Figure [6H](#F6){ref-type="fig"}). The mean MDA level in the Sal B group was 40.67 ± 5.05 nM mg^-1^ protein^-1^ compared to 50.83 ± 6.70 nM mg^-1^ protein^-1^ in the Sal B + 3MA group (*p* = 0.014; Figure [6I](#F6){ref-type="fig"}). On day 3, there were no significant differences in the flap survival area between the Sal B and Sal B + 3MA groups (Figure [7A](#F7){ref-type="fig"}). On day 7, the necrosis of flaps became darker and the Sal B group had a significantly larger mean survival area than the Sal B + 3MA group (65.66 ± 10.20 and 45.42 ± 11.85%, respectively; *p* = 0.010; Figure [7B](#F7){ref-type="fig"}). Figure [7C](#F7){ref-type="fig"} shows edema on the inner side of the flaps. The water content of tissue was significantly lower in the Sal B group (48.49 ± 7.34%) than in the Sal B + 3MA group (58.72 ± 7.92%; *p* = 0.043; Figure [7D](#F7){ref-type="fig"}). The Sal B group had a larger blood flow area than the Sal B + 3MA group (Figure [7E](#F7){ref-type="fig"}). The percentage LDBF area was significantly greater in the Sal B group than in the Sal B + 3MA group (40.08 ± 9.86 and 22.57 ± 6.20%, respectively; *p* = 0.004; Figure [7F](#F7){ref-type="fig"}). In addition, H&E staining showed that the Sal B group had a greater number of microvessels than the Sal B + 3MA group (Figure [7G](#F7){ref-type="fig"}). The MVD of area II in the Sal B group was significantly higher than that in the Sal B + 3MA group (32.69 ± 8.61/mm^2^ and 19.34 ± 5.85/mm^2^, respectively; *p* = 0.023; Figure [7H](#F7){ref-type="fig"}). Moreover, 3MA decreased the number of CD34-positive vessels (34.73 ± 8.91/mm^2^ in the Sal B + 3MA group, compared with the Sal B group (18.67 ± 7.87/mm^2^; *p* = 0.006; Figures [7I,J](#F7){ref-type="fig"}).

![Inhibition of autophagy reverses the effects of Sal B in random skin flaps. Rats were killed and the samples in middle part of flap area II were harvested for analysis on post-operative day 7. **(A)** Autophagy level in skin flaps were estimated by immunofluorescence staining of LC3II:Autophagosomes (green) in the dermis in area II in each group; nuclei counterstained with DAPI (blue) (scale bar: 15 μm). **(B)** Histogram of frequency of LC3II-positive cells in the dermis. **(C)** Western blotting of Beclin1, VPS34, CTSD, LC3II, and p62 levels, as well as those of MMP9, VEGF, and cadherin 5, corrected by GAPDH as internal control. The gels have been run under the same experimental conditions. The original images are available in Supplementary Figures [S2A,B](#SM2){ref-type="supplementary-material"}. **(D)** Histograms of optical density values of autophagy- (Beclin1, VPS34, CTSD, LC3II, and p62) and angiogenesis- (MMP9, VEGF, and cadherin 5) related proteins, assessed by Western blotting. **(E)** Western blotting of Bax, CYC, and caspase 3 levels, as well as those of SOD1, eNOS, and HO1, corrected by GAPDH as internal control. The original images are available in Supplementary Figures [S2C,D](#SM2){ref-type="supplementary-material"}. **(F)** Histograms of optical density values of apoptosis- (Bax, CYC, and caspase 3) and oxidative stress-related proteins (Bax, CYC, and caspase 3) as determined by Western blotting. **(G)** Total SOD activity by xanthine oxidase method. **(H)** GSH level by modified 5,5′-dithiobis \[2-nitrobenzoic acid\] method. **(I)** MDA level by modified thiobarbituric acid test. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 vs. the control group. Data are means ± SEM (*n* = 6 per group); NS, not significant.](fphar-09-01178-g006){#F6}

![Inhibition of autophagy reverses the effects of Sal B on flap vitality. **(A)** Digital photographs of flap survival of the Control and Sal B group on post-operative days 3 and 7 (scale bar: 2 cm). **(B)** Histogram of percentages of flap survival area on post-operative day 7. **(C)** Digital photographs of the inner side of skin flaps in each group on post-operative day 7 showing the degree of edema (scale bar: 2 cm). **(D)** Histogram of percentages of tissue water content of skin flaps. **(E)** LDBF imaging showing vascular flow and blood supply in skin flaps on post-operative day 7 (scale bar: 2 cm). **(F)** Histogram of percentages of area of blood supply. **(G)** H&E staining of microvessels in area II of skin flaps (original magnification: 200×; scale bar: 50 μm). **(H)** Histogram of MVDs as determined by H&E staining. **(I)** IHC for CD34 in area II of skin flaps (original magnification: 200×; scale bar: 50 μm). **(J)** Histogram of CD34-positive vessel densities. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 vs. the control group. Data are means ± SEM (*n* = 6 per group).](fphar-09-01178-g007){#F7}

Discussion
==========

Sal B, an extract of *S. miltiorrhiza*, is used for the treatment of various vascular diseases involving the cardiovascular system ([@B22]), cerebral small blood vessels ([@B39]), and osteonecrosis of the femoral head in TCM ([@B20]). Ischemia and necrosis in the distal part of random skin flaps due to a reduced blood supply are commonly encountered in plastic and reconstructive surgery. However, evidence-based data on the efficacy of Sal B in random-pattern skin flaps are limited. Our data suggest that Sal B promotes the survival of random skin flaps by inducing autophagy and angiogenesis, as well as attenuating oxidative stress and apoptosis.

Sal B enhances angiogenesis in murine SVR endothelial cells *in vitro* ([@B17]), as well as in animal models of myocardial infarction ([@B22]). In our study, H&E and IHC staining for CD34 showed that Sal B significantly increased the number of microvessels in the dermis of ischemic flaps. Moreover, vascular flow was greater in the Sal B group than in the control group. These findings indicate that Sal B promotes the survival of random skin flaps by increasing their blood supply. Angiogenesis involves destruction of preexisting cell connections, mitosis, sprouting of endothelial cells, and maturation of new capillaries ([@B25]). MMP9 degrades proteins related to vessel wall stability ([@B21]), VEGF induces mitosis of endothelial cells ([@B31]), and cadherin 5 forms intercellular junctions. Western blotting and IHC indicated that Sal B increased VEGF and cadherin 5 expression in the dermis of ischemic flaps. Furthermore, MMP9 levels were higher in the Sal B group than in the control group. Thus, Sal B promotes angiogenesis in the dermis of random skin flaps.

In random skin flaps, post-ischemic reperfusion induces oxidative stress and apoptosis, leading to tissue damage ([@B16]). In the early stages of oxidative stress, ROS react with cell membrane lipids and proteins, triggering peroxidation and destruction of cells ([@B1]). As a marker of lipid peroxidation, the MDA level reflects the extent of tissue injury ([@B37]). Furthermore, SOD and GSH are indicators of antioxidant status ([@B11]), eNOS has antioxidant activity ([@B34]; [@B45]), and HO1 is expressed during the oxidative stress response ([@B6]). Sal B promotes functional recovery from cerebral vessel disease by reducing oxidative stress ([@B39]). Western blotting and IHC indicated that Sal B increased SOD1, eNOS, and HO1 expression in the dermis of ischemic flaps. Moreover, it increased the SOD and GSH levels, and decreased the MDA level, in ischemic flaps. In short, Sal B attenuates the level of oxidative stress in random skin flaps.

Sal B reportedly prevents apoptosis in various ischemic diseases such as hepatic IRI, and acute myocardial infarction ([@B15]; [@B22]). The pathologic mechanism of necrosis of ischemic flaps after post-ischemic perfusion involves apoptosis ([@B28]). Therefore, we hypothesized that Sal B inhibits apoptosis in areas of ischemia, which promotes the survival of random-pattern skin flaps. Thus, we analyzed apoptosis in areas of ischemia in the skin flaps. Mitochondria are centrally located during apoptosis ([@B48]). Bax induces permeabilization of the mitochondrial outer membrane, leading to swelling ([@B41]). CYC is released from mitochondria and forms an apoptosome, which activates caspase 3 to induce apoptosis ([@B48]). Hence, Bax, CYC, and caspase 3 levels were determined to analyze the magnitude of apoptosis. The caspase 3 level in area II was markedly decreased by Sal B. Moreover, Western blotting showed that Bax and CYC levels were significantly lower in the Sal B group than in the control group. Therefore, Sal B inhibits apoptosis in random skin flaps.

Autophagy is a natural, regulated mechanism for the degradation of unnecessary or dysfunctional components such as cytosolic macromolecules and organelles, and it protects against metabolic stress ([@B12]; [@B30]). In disease, autophagy is an adaptive response to stress, which promotes survival, whereas in other situations it promotes cell death ([@B7]). Autophagy is important in vascular disease including acute myocardial infarction and cerebral small blood vessel disease ([@B22]; [@B39]). Furthermore, Sal B reportedly promotes autophagy in vascular disease ([@B19]). However, the role of autophagy in random skin flaps is unclear. To the best of our knowledge, this is the first study on the effects of Sal B on autophagy in random skin flaps. Autophagy involves autophagosome formation, autolysosome formation, and substrate degradation. Therefore, we analyzed Beclin1, VPS34, and LC3II as markers of autophagosomes ([@B44]), CTSD as a marker of autolysosomes ([@B42]), and p62 as a marker of autophagic degradation ([@B46]; [@B47]). Immunofluorescence revealed that LC3II and CTSD expression were greater in the Sal B group. Moreover, Beclin1, LC3II, and VPS34 expression were upregulated, which indicates an increase in the number of autophagosomes in areas of ischemia. Next, we assessed autophagic degradation by evaluating p62 and CTSD levels. The CTSD level was higher, and that of p62 was lower, in the Sal B group than in the control group, which indicates enhanced autophagic flux in the Sal B group. Therefore, Sal B activates autophagy in random skin flaps.

We also evaluated the role of Sal B-induced autophagy in random skin flaps. Inhibition of autophagy by 3MA reversed the Sal B-induced increase in survival, reduction of tissue edema, and increase in microvessel density. Autophagy promotes angiogenesis by activating AKT phosphorylation in endothelial cells ([@B26]). We found that administration of 3MA significantly reduced MMP9 and cadherin 5 levels. Therefore, Sal B promotes angiogenesis in random skin flaps by activating autophagy. Autophagy also degrades polyubiquitinated proteins and damaged mitochondria to prevent ER stress-induced mitochondria-mediated apoptosis ([@B36]; [@B18]). In present study, Bax, CYC, and caspase 3 levels were decreased by 3MA, which suggests that the anti-apoptosis effects of Sal B are mediated by activation of autophagy. In addition, autophagy is required to maintain healthy mitochondria to prevent the release of ROS from damaged mitochondria ([@B24]). In this study, 3MA significantly decreased the SOD, SOD1, eNOS, HO1, and GSH levels, and increased that of MDA, in Sal B-treated flaps. Thus, Sal B reduces oxidative stress in random skin flaps by activating autophagy.

However, it is no doubt that the limitations of Sal B in the random skins therapy still need to be further investigated. For example, There are many active molecules and pharmaceuticals, such as VEGF(165), calcitriol, curculigoside A, have been shown to increase the survival of random pattern skin flaps in rats ([@B8]; [@B49]; [@B4]). However, none of them have come to clinical application. Application in large animal model (proof of concept as a preclinical study) will be beneficial in these studies. Therefore, for further translational research, rabbit or pig will be used to verify the beneficial effect of Sal B on the flaps survival. Moreover, the Sal B treatment used 7 days before the surgery is also hard to apply clinically. Therefore, the time of Sal B administration for the flap survival promotion beginning after the surgery is needed to be investigated.

Conclusion
==========

Sal B has pro-angiogenesis, anti-apoptosis, and anti-oxidative stress effects by promoting autophagy, which enhances the survival of random-pattern skin flaps.
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Sal B

:   salvianolic acid B
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